Health Economics›Chronic lymphocytic leukemia›First-line therapy randomized data

First-line therapy randomized data

Chronic lymphocytic leukemia · 24 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 10 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Chlorambucil and Ofatumumab Variant #01	—	R 1 179 868	28d	22.4 mo	—	12	R 6 319 741 PFS proxy	1
Ibrutinib, Venetoclax, Obinutuzumab Variant #01	—	R 295 786	28d	—	—	14	R 2 457 326 PFS proxy	2
Alemtuzumab monotherapy Variant #03	—	R 267 680	7d	15.0 mo	—	1	R 267 680 PFS proxy	—
Venetoclax and Obinutuzumab Variant #01	—	R 240 071	28d	76.2 mo	—	10	R 1 214 514 PFS proxy	6
Ibrutinib and Venetoclax Variant #01	—	R 200 392	28d	—	—	24	R 3 899 215 PFS proxy	9
Ibrutinib and Rituximab Variant #02	—	R 183 752	28d	—	—	6	R 688 035 PFS proxy	3
Ibrutinib and Obinutuzumab Variant #01	—	R 175 528	28d	—	—	7	R 751 720 PFS proxy	1
Acalabrutinib and Obinutuzumab Variant #01	—	R 174 612	28d	—	—	8	R 824 528 PFS proxy	3
Fludarabine and Alemtuzumab Variant #02	—	R 162 512	28d	23.7 mo	—	6	R 537 050 PFS proxy	2
FCR Variant #07	—	R 120 349	30d	57.6 mo	—	5	R 361 047 PFS proxy	9
Bendamustine and Rituximab (BR) and Ibrutinib Variant #01	—	R 111 351	28d	—	—	~7	~R 618 713 PFS proxy · indirect	2
Chlorambucil and Obinutuzumab (GClb) Variant #01	—	R 96 236	28d	27.8 mo	—	12	R 200 881 PFS proxy	10
FCA Variant #01	—	R 89 696	28d	—	—	6	R 270 498 PFS proxy	1
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	106.8 mo	—	2	R 163 929 PFS proxy	10
Acalabrutinib monotherapy Variant #01	—	R 79 217	28d	—	—	2	R 158 435 PFS proxy	2
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	2	R 131 500 PFS proxy	2
Chlorambucil and Rituximab (RClb) Variant #01	—	R 52 650	42d	23.1 mo	—	6	R 160 474 PFS proxy	2
Cladribine monotherapy Variant #03	—	R 34 921	35d	—	—	~1	~R 34 921 indirect	—
FCR (SC Rituximab) Variant #01 Partial	—	R 34 345	28d	—	—	~6	~R 76 547 indirect	—
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	43.2 mo	—	8	R 270 994 PFS proxy	6
Obinutuzumab monotherapy Variant #06	—	R 23 849	21d	—	—	~4	~R 95 395 indirect	—
Cladribine and Cyclophosphamide (CC) Variant #01	—	R 20 143	28d	—	—	~6	~R 120 858 indirect	—
Bendamustine monotherapy Variant #01	—	R 7 084	—	19.1 mo	—	8	R 56 672 PFS proxy	—
Watchful waiting Partial	—	—	—	12.9 mo	—	—	—	—

24 of 24 regimens shown